Alemtuzumab induction in pediatric kidney transplantation.

Challenges in pediatric renal transplantation. World J Transplant (2014) 0.77

Alemtuzumab induction in pediatric kidney transplantation. Pediatr Transplant (2013) 0.75

Renal Transplantation From a Living Donor With a Horseshoe Kidney. Transplant Direct (2015) 0.75

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70

Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09

Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86

Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2.51

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26

Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Transplantation (2008) 1.52

Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation. J Pediatr (2006) 1.36

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant (2005) 1.22

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood (2002) 1.18

Campath-1H use in pediatric renal transplantation. Am J Transplant (2005) 1.13

Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. Transplantation (2011) 1.06

Campath-1H monoclonal antibody therapy. Curr Opin Oncol (2000) 1.01

Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant (2008) 0.98

Some observations on prope tolerance. Curr Opin Organ Transplant (2011) 0.89

Dendritic cells: tools and targets for transplant tolerance. Am J Transplant (2005) 0.86

Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation. Clin Transplant (2011) 0.85

Calcineurin inhibitor withdrawal in stable kidney transplant patients decreases the donor-specific cytotoxic T lymphocyte precursor frequency. Transplantation (2005) 0.83

Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol (2006) 0.82

Prevalence and subtypes of BK virus in pediatric renal transplant recipients in Russia. Pediatr Transplant (2012) 0.81

Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. J Am Soc Nephrol (1997) 0.80

657del5 mutation in the gene for Nijmegen breakage syndrome (NBS1) in a cohort of Russian children with lymphoid tissue malignancies and controls. Am J Med Genet A (2003) 0.88

A study of online consultations for paediatric renal patients in Russia. J Telemed Telecare (2010) 0.81

Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol (2014) 0.78

Response of pure red cell aplasia to cyclophosphamide after failure of mycofenolate mofetil in a patient with polyglandular syndrome type I. J Pediatr Hematol Oncol (2013) 0.75